Edurant

Edurant is a brand name of rilpivirine, approved by the FDA in the following formulation(s):

EDURANT (rilpivirine hydrochloride - tablet; oral)

• 
  Manufacturer: TIBOTEC
  
  Approval date: May 20, 2011
  
  Strength(s): EQ 25MG BASE ^[RLD]

Has a generic version of Edurant been approved?

No. There is currently no therapeutically equivalent version of Edurant available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Edurant. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  2,4-Di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineaoplastic agents
  Patent 6,838,464
  Issued: January 4, 2005
  Inventor(s): Pease; Elizabeth Janet & Williams; Emma Jane & Bradbury; Robert Hugh & Pearson; Stuart Eric
  Assignee(s): AstraZeneca AB
  Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
  
  Patent expiration dates:
  
  
  • February 26, 2021
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  2,4,DI (hetero-) arylamino (-oxy)-5-substituted pyrimidines as antineoplastic agents
  Patent 7,067,522
  Issued: June 27, 2006
  Inventor(s): Pease; Elizabeth Janet & Williams; Emma Jane & Bradbury; Robert Hugh & Pearson; Stuart Eric
  Assignee(s): AstraZeneca AB
  Pyrimidine derivatives of formula (I) wherein Q1, Q2, G and R1 are as defined within; and pharmaceutically acceptable salts and in vivo hydrolysable esters thereof are described. Processes for their manufacture, pharmaceutical compositions and their use as cyclin-dependent serine/threonine kinase (CDK) and focal adhesion kinase (FAK) inhibitors are also described.
  
  Patent expiration dates:
  
  
  • December 20, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  HIV inhibiting pyrimidines derivatives
  Patent 7,125,879
  Issued: October 24, 2006
  Inventor(s): Guillemont; Jérôme Emile Georges & Palandjian; Patrice & de Jonge; Marc René & Koymans; Lucien Maria Henricus & Vinkers; Hendrik Maarten & Daeyaert; Frederik Frans Desiré & Heeres; Jan & Van Aken; Koen Jeanne Alfons & Lewi; Paulus Joannes
  Assignee(s): Janssen Pharmaceutica N.V.
  This invention concerns HIV replication inhibitors of formula (I) the N-oxides, the pharmaceutically acceptable addition salts, the quaternary amines and the stereochemically isomeric forms thereof, wherein the ring containing −a1=a2−a3=a4—and −b1=b2−b3=b4represents pheynl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl; n is 0 to 5; m is 1 to 4; R1 is hydrogen; aryl; formyl; C1-6alkylcarbonyl; C1-6alkyl; C1-6alkyloxycarbonyl, substituted C1-6alkyl, C1-6alkylcarbonyl; R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH?2?, —NHC(═O)R6, —C(═NH)R6 or a 5-membered hetrocycl; X1 is —NR5—, —NH—NH—, —N═N—, —O—, —C(═O)—, C1-4alkanediyl, —CHOH—, —S—, —S(═O)p—, —X2—C1-4alkanediyl- or —C1-4alkanediyl-X2—; R3 is NHR13, NR13R14; —C(═O)—NHR13; —C(═O)—NR13R14; —C(═O)—R15; —CH═N—NH—C(═O)—R16; substituted C1-6alkyl; optionally substituted C1-6alkyloxyC1-6alkyl; substituted C2-6alkenyl; substituted C2-6alkynyl; substituted C2-6alkylenyl; C1-6alkyl substituted with hydroxy and a second substituent; —C(═N—O—R8)—C1-4alkyl; R7; or —X3—R7; R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl) amino; their use as a medicine, their processes for preparation and pharmaceutical compositions comprising them
  
  Patent expiration dates:
  
  
  • April 14, 2023
    
    ✓ 
    Patent use: IN COMBINATION WITH OTHER ANTIRETROVIRAL AGENTS, IS INDICATED FOR THE TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) INFECTION IN ANTIRETROVIRAL TREATMENT-NAIVE ADULT PATIENTS, AS SET FORTH IN THE LABELING, INCLUDING I&U SECTION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
  Patent 7,638,522
  Issued: December 29, 2009
  Inventor(s): Guillemont; Jérôme Emile Georges & Stevens; Paul Theodoor Agnes & Copmans; Alex Herman & Peeters; Jozef & Stappers; Alfred Elisabeth & Vandecruys; Roger Petrus Gerebern & Stoffels; Paul
  Assignee(s): Janssen Pharmaceutica N.V.
  The present invention relates to a pharmaceutical composition comprising as active ingredient the hydrochloric acid salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethyl-phenyl]amino]-2-pyrimidinyl]amino]benzonitrile and to processes for their preparation.
  
  Patent expiration dates:
  
  
  • April 14, 2023
    
    ✓ 
    Drug product
  
  



• 
  HIV inhibiting pyrimidines derivatives
  Patent 8,080,551
  Issued: December 20, 2011
  Inventor(s): Guillemont; Jérôme Emile Georges & Palandijian; Patrice & De Jonge; Marc René & Koymans; Lucien Maria Henricus & Vinkers; Hendrik Maarten & Daeyaert; Frederik Frans Desiré & Heeres; Jan & Van Aken; Koen Jeanne Alfons & Lewi; Paulus Joannes & Janssen;
  Assignee(s): Janssen Pharmaceutica N.V.
  HIV replication inhibitors having formula (I) defined herein are disclosed. Pharmaceutical compositions containing the HIV replication inhibitors; the use of the HIV replication inhibitors in the treatment of HIV; and processes for preparing the HIV replication inhibitors are also disclosed.
  
  Patent expiration dates:
  
  
  • April 11, 2023
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 20, 2016 - NEW CHEMICAL ENTITY
  
  

See also...

• Edurant Consumer Information (Drugs.com)
• Edurant Consumer Information (Wolters Kluwer)
• Edurant Consumer Information (Cerner Multum)
• Edurant Advanced Consumer Information (Micromedex)
• Rilpivirine Consumer Information (Wolters Kluwer)
• Rilpivirine Consumer Information (Cerner Multum)
• Rilpivirine Advanced Consumer Information (Micromedex)